Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 8012345...102030...Last »

J&J hit with $247 million verdict in hip implant trial

A federal jury in Dallas ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Read More »

TokBox reveals “Live Video Maturity Study” results

The live video, real-time communications company (RTC) TokBox announced the results of its inaugural “Live Video Maturity Study.”

Read More »

Acorda reports five deaths in Parkinson’s trial

Acorda Therapeutics Inc. said five people died in clinical trials for the company’s Parkinson’s disease drug, the latest in a series of setbacks for the drugmaker.

Read More »

Mylan Chops Another 200 to 300 Jobs

Mylan reportedly let go between 200 and 300 people from its West Virginia operations.

Read More »

Loxo Oncology, Bayer Strike Cancer Deal

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.

Read More »

Zymeworks, Janssen Biotech Ink R&D Deal

Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.

Read More »

W2O Group Expands Chicago Presence

W2O Group, a network of innovative analytics-driven, digital-first marketing and communications firms, announced the appointment of three senior executives in its growing Chicago office.

Read More »

Boehringer, MiNA Therapeutics Forge NASH Deal

Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.

Read More »

GSK appoints new R&D head

GlaxoSmithKline poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head.

Read More »

Regeneron’s Q3 2017 profit tops Street view

Regeneron Pharmaceuticals reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for its flagship eye treatment Eylea and new eczema drug Dupixent.

Read More »

Mallinckrodt slumps as Acthar drug sales disappoint

Shares of Mallinckrodt Plc were down after the drugmaker reported lower-than-expected quarterly revenue.

Read More »

Layoffs in California: Amgen to Slash 200 R&D Jobs, Genentech to Cut 130

Roche company Genentech indicated it is laying off 130 people at its facility in Vacaville, Calif. by the end of 2017. Amgen is reportedly eliminating about 200 R&D jobs, mostly in California, by the end of 2017.

Read More »

SEC Charges Osiris, Four Former Execs With Accounting Fraud

Osiris Therapeutics settled a case of accounting fraud with the U.S. SEC, but four former company executives will face charges for the alleged financial misreporting.

Read More »

Sanofi Falls Short of Q3 2017 Expectations

The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in third-quarter 2017.

Read More »

Precision Value & Health Forms Global Market Access Consultancy: Precision Xtract

Precision Value & Health announced the formation of Precision Xtract – a new, focused alignment of the company’s global market access consulting services.

Read More »

Novo Nordisk warns of U.S. legislation

Drugmaker Novo Nordisk warned that draft legislation in some U.S. states to make pricing more transparent could impact business in the company’s largest market.

Read More »

Pfizer beats Q3 2017 profit estimates

Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.

Read More »

Publicis Health Integrates Publicis LifeBrands Medicus Into Saatchi & Saatchi Wellness

Publicis Health announced the integration of Publicis LifeBrands Medicus (PLBM) into Saatchi & Saatchi Wellness (SSW) to create a new Wellness Intelligence-driven agency designed to help health and wellness-oriented audiences navigate the expanding “Wellness Culture.”

Read More »

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise

AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.

Read More »

CVS reportedly makes bid for Aetna

U.S. pharmacy operator CVS Health Corp. made an offer to acquire No. 3 U.S. health insurer Aetna Inc. for more than $200 per share, or over $66 billion, sources said.

Read More »

Page 1 of 8012345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!


Ad Right Bottom

Main Navigation